Literature DB >> 16931958

Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases.

Russell Vang1, Allen M Gown, Todd S Barry, Darren T Wheeler, Anna Yemelyanova, Jeffrey D Seidman, Brigitte M Ronnett.   

Abstract

Coordinate expression profiles for cytokeratins 7 and 20 (CK7 and CK20) are useful for distinguishing certain types of adenocarcinomas but use for distinction of primary and secondary mucinous tumors in the ovary is limited due to the existence of a number of tumor types exhibiting overlapping CK7/CK20 immunoprofiles; the use of staining distribution patterns in the distinction of tumors with shared profiles has not been evaluated in detail. We report analysis of both coordinate expression profiles and staining distribution in 179 rigorously classified mucinous tumors in the ovary, including 53 primary tumors [35 atypical proliferative (borderline) mucinous tumors of gastrointestinal type and 18 invasive mucinous carcinomas] and 126 secondary tumors [28 colorectal adenocarcinomas, 54 appendiceal tumors (23 adenocarcinomas, 31 low-grade adenomatous mucinous tumors associated with pseudomyxoma peritonei), 14 pancreatic adenocarcinomas, 8 endocervical adenocarcinomas, 5 gastric adenocarcinomas, 4 gallbladder/biliary tract adenocarcinomas, and 13 adenocarcinomas of unknown primary sites). A CK7+/CK20+ immunoprofile was the most common profile in primary ovarian tumors (74%), upper gastrointestinal tract tumors (78%), and endocervical tumors (88%) but was occasionally observed in lower intestinal tract tumors (colorectal: 11%; appendiceal: 13% of low-grade tumors, 35% of carcinomas). A CK7-/CK20+ immunoprofile was the most common profile in lower intestinal tract tumors (79%) and was uncommon in upper gastrointestinal tract tumors (9%), rarely seen in primary ovarian tumors (4%), and not seen in endocervical tumors. A CK7+/CK20- profile was observed in some primary ovarian (23%), upper gastrointestinal tract (13%), and endocervical tumors (13%) but not in lower intestinal tract tumors. For CK7+ tumors, staining distribution was very frequently diffuse (>50% of tumors cells positive) in primary ovarian, upper gastrointestinal tract, and endocervical tumors, whereas staining distribution was often focal (<50% of tumors cells positive) when present in colorectal and appendiceal carcinomas but not in low-grade appendiceal tumors. For CK20+ tumors, staining distribution was variable but often focal in primary ovarian tumors and nonlower intestinal tract tumors, whereas the pattern was almost always diffuse in lower intestinal tract tumors. Immunohistochemical staining distribution can supplement CK7/CK20 coordinate expression profiles to distinguish subsets of primary ovarian and metastatic lower intestinal tract mucinous tumors having overlapping immunoprofiles but neither coordinate expression profiles nor staining distribution distinguishes primary ovarian tumors from the nonlower intestinal tract metastases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16931958     DOI: 10.1097/01.pas.0000213281.43036.bb

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  39 in total

1.  CDX2 as a marker for intestinal differentiation: Its utility and limitations.

Authors:  Reda S Saad; Zeina Ghorab; Mahmoud A Khalifa; Mei Xu
Journal:  World J Gastrointest Surg       Date:  2011-11-27

2.  Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study.

Authors:  Richard J Zaino; Mark F Brady; Subodh M Lele; Helen Michael; Benjamin Greer; Michael A Bookman
Journal:  Cancer       Date:  2010-09-22       Impact factor: 6.860

3.  Ovarian recurrence from a Stage 1b1 cervical adenocarcinoma previously treated with radical vaginal trachelectomy: A case report.

Authors:  E C Brockbank; J Evans; N Singh; J H Shepherd; A R Jeyarajah
Journal:  Gynecol Oncol Case Rep       Date:  2012-01-16

Review 4.  [Morphology of secondary ovarian tumors and metastases].

Authors:  L-C Horn; J Einenkel; R Handzel; A K Höhn
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

5.  Challenging diagnosis of a jejunal adenocarcinoma with ovarian metastasis: report of an unusual case.

Authors:  Yang Yang Huang; Jeremy John Pratt; Marcus Dabner; William Tjhin
Journal:  BMJ Case Rep       Date:  2013-04-10

6.  Mucinous adenocarcinoma involving the ovary: comparative evaluation of the classification algorithms using tumor size and laterality.

Authors:  Eun Sun Jung; Jeong Hoon Bae; Ahwon Lee; Yeong Jin Choi; Jong-Sup Park; Kyo-Young Lee
Journal:  J Korean Med Sci       Date:  2010-01-19       Impact factor: 2.153

7.  Occult gallbladder carcinoma presenting as a primary ovarian tumor in two women: two case reports and a review of the literature.

Authors:  Yashwant Kumar; Alka Chahal; Monika Garg; Anjali Bhutani
Journal:  J Med Case Rep       Date:  2010-06-30

8.  Undifferentiated pelvic adenocarcinomas: diagnostic potential of protein profiling and multivariate analysis.

Authors:  U J Roblick; F G Bader; C Lenander; U Hellman; K Zimmermann; S Becker; A Ost; A Alaiya; H-P Bruch; R Keller; L Mirow; B Franzén; T Ried; G Auer; J K Habermann
Journal:  Int J Colorectal Dis       Date:  2008-02-22       Impact factor: 2.571

Review 9.  [Mucinous ovarian neoplasms. Prognostically mostly excellent, infrequently a wolf in sheep's clothing].

Authors:  S Lax; A Staebler
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

10.  HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy.

Authors:  Jessica N McAlpine; Kimberly C Wiegand; Russell Vang; Bridgett M Ronnett; Anna Adamiak; Martin Köbel; Steve E Kalloger; Kenneth D Swenerton; David G Huntsman; C Blake Gilks; Dianne M Miller
Journal:  BMC Cancer       Date:  2009-12-10       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.